Bladder Cancer Advocacy Network
This study aims to better understand how treatment choices impact outcomes for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC), as well as the factors that influence treatment decisions made by patients and their healthcare providers. The study will also include patients with muscle-invasive bladder cancer (MIBC). In addition to receiving standard care and routine follow up, these patients will provide blood samples over time. Researchers will analyze these samples for circulating tumor DNA (ctDNA), small fragments of DNA released into the bloodstream by cancer cells, to monitor how the cancer responds to treatment. The information gained from this study may help improve treatment planning, disease monitoring, and overall outcomes for patients with bladder cancer.
This is a multi-center study whose aim is to understand outcomes based on treatment decisions for patients with intermediate and high risk NMIBC and to understand rationale for treatment decisions for patients and providers. The study will also enroll participants with MIBC who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance. The study will explore the use of non-invasive plasma ctDNA biomarkers to capture disease evolution and response to therapy for the potential development of an assay for early detection of r…
Inclusion Criteria: Arms I-IV * Meet criteria for intermediate risk or high risk (BCG naïve, BCG exposed or BCG unresponsive disease) * English speakers * 18 years of age or older * Ability to understand and the willingness to provide an informed consent * Pathology documentation from any hospital/clinic/medical center, and * Predominant urothelial carcinoma histology in the specimen * Patients undergoing any treatment including observation are eligible for inclusion * Patients enrolling on clinical trial are eligible for participation * Any patient previously meeting criteria for BCG unresp…
This is a non-interventional, observational prospective study: Arms I-V reflect patient/provider choices, and patients may receive multiple interventions. This is a non-interventional observational study, exposures are not study-assigned interventions.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.